Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase IIb study of RGN 259 eye drops for the treatment of moderate to severe dry eye in China

Trial Profile

A phase IIb study of RGN 259 eye drops for the treatment of moderate to severe dry eye in China

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 23 Oct 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Timbetasin (Primary)
  • Indications Dry eyes; Keratoconjunctivitis sicca
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Lees Pharmaceutical Holdings
  • Most Recent Events

    • 23 Oct 2015 According to RegeneRx Biopharmaceuticals media release, company received notice from China's FDA (CFDA) declining its IND application because the API was manufactured outside of China.
    • 17 Feb 2015 This trial is expected to be initiated before the third quarter of 2015, with results in late 2015 or early 2016, according to a RegeneRx media release.
    • 17 Feb 2015 Lees Pharmaceutical Holdings is awaiting regulatory approval to begin this dose-response study, according to a RegeneRx media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top